×
About 3,748 results

ALLMedicine™ Retinal Vein Occlusion Center

Research & Reviews  1,176 results

The Correlation between Obstructive Sleep Apnea and Retinal Vein Obstruction: A Meta-An...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9296346
Contrast Media & Molecular Imaging; Qin Z, Li X et. al.

Aug 9th, 2022 - Despite of inadequate evidence, previous studies have demonstrated a potential correlation between obstructive sleep apnea (OSA) and retinal vein occlusion (RVO). In this study, a meta-analysis is conducted to investigate the correlation between O...

Macrophages in close proximity to the vitreoretinal interface are potential biomarkers ...
https://doi.org/10.1186/s12974-022-02562-3
Journal of Neuroinflammation; Rajesh A, Droho S et. al.

Aug 9th, 2022 - Diabetic retinopathy and retinal vein occlusion are vision threatening retinal vascular diseases. Current first-line therapy targets the vascular component, but many patients are treatment-resistant due to unchecked inflammation. Non-invasive infl...

Risks of posterior segment ocular ischaemic events in patients with systemic lupus eryt...
https://doi.org/10.1136/bjo-2022-321653
The British Journal of Ophthalmology; Chiou YR, Chang YS et. al.

Aug 4th, 2022 - Ocular involvement in systemic lupus erythematosus (SLE) is often primarily recognised by ophthalmologists rather than internists. This study aims to investigate the incidence and risk factors for the occurrence of posterior ocular ischaemic event...

Ocular manifestations of COVID-19 in the pediatric age group.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339424
European Journal of Ophthalmology; Alnahdi MA, Alkharashi M

Jul 29th, 2022 - The coronavirus disease 2019 (COVID-19) is now known to be associated with several ocular manifestations. The literature thoroughly discussed those that affect adults, with a lesser focus in the pediatric age group. We aim to outline the various p...

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
https://clinicaltrials.gov/ct2/show/NCT03802630

Jul 28th, 2022 - The study was comprised of a Screening period (Day -28 to Day -1), Double-masked treatment period (Day 1 to Week 72) and Post-treatment follow-up period (Week 72 to Week 76). Treatment visits were scheduled in 4-week intervals. After 6 initial mon...

see more →

Drugs  7 results see all →

Clinicaltrials.gov  226 results

Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
https://clinicaltrials.gov/ct2/show/NCT03802630

Jul 28th, 2022 - The study was comprised of a Screening period (Day -28 to Day -1), Double-masked treatment period (Day 1 to Week 72) and Post-treatment follow-up period (Week 72 to Week 76). Treatment visits were scheduled in 4-week intervals. After 6 initial mon...

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion
https://clinicaltrials.gov/ct2/show/NCT04740931

Jul 26th, 2022 - This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at 4-week intervals unt...

Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice
https://clinicaltrials.gov/ct2/show/NCT04137120

Jul 25th, 2022 - The primary objective is to assess the safety of intravitreal aflibercept injections in patients with wet age-related macular degeneration (wAMD), myopic choroidal neovascularization (mCNV), diabetic macular edema (DME), macular edema secondary to...

A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
https://clinicaltrials.gov/ct2/show/NCT04592419

Jul 22nd, 2022 - This is a Phase 3, prospective, randomized, double-masked, two-arm, multi-center non-inferiority study evaluating the efficacy and safety of repeated intravitreal dosing of KSI-301 5 mg in participants with visual impairment due to treatment-naïve...

Suprachoroidal Triamcinolone Versus Posterior Subtenon Triamcinolone Alone or Formulated in the Management of Diabetic Macular Edema.
https://clinicaltrials.gov/ct2/show/NCT05464953

Jul 19th, 2022 - Background Retinal vascular disorders, such as diabetic retinopathy, hypertensive retinopathy, retinal hemorrhage, and retinal vein occlusion are significant causes of vision impairment and blindness worldwide. Diabetic retinopathy (DR) is the mos...

see more →

News  88 results

COVID-19 May Increase Risk for Rare Eye Clots
https://www.medscape.com/viewarticle/972265

Apr 18th, 2022 - (Reuters) - Patients with COVID-19 may have an increased risk of rare vision-threatening blood clots in the eye for months afterward, new findings suggest. Because SARS-CoV-2 infections increase the risk of blood vessel obstructions at other sites...

Vision-Threatening Retinal Condition Linked to COVID-19
https://www.medpagetoday.com/ophthalmology/generalophthalmology/98212

Apr 14th, 2022 - COVID-19 infection may be boosting the numbers of a rare ocular condition in which vision is threatened when veins in the retina are blocked, eye specialists in Southern California report. Risk of retinal vein occlusion was higher in the 6 months ...

FDA Approves First Biosimilar for Ranibizumab Intravitreal Injections, nAMD
https://www.medscape.com/viewarticle/959087

Sep 20th, 2021 - The US Food and Drug Administration (FDA) has approved the first biosimilar for ophthalmology, Byooviz (ranibizumab-nuna), which will be indicated for neovascular (wet) age-related macular degeneration (nAMD), macular edema following retinal vein ...

COVID Delay of Treatment of Neovascular Age-Related Macular Degeneration Less Harmful Than Expected
https://www.medscape.com/viewarticle/950709

May 6th, 2021 - Many people with neovascular age-related macular degeneration (nAMD) lost less vision than expected during treatment delays imposed by COVID-19, researchers say. The finding suggests that physicians may be overtreating these patients, said James T...

Novel Agents Revolutionize Melanoma Treatment
https://www.onclive.com/view/novel-agents-revolutionize-melanoma-treatment

Dec 5th, 2020 - The mechanism of action of vemurafenib (Zelboraf) in inhibiting BRAF activity. Until recently, the cornerstone of therapy for metastatic melanoma had been chemotherapy with dacarbazine (DTIC) and immunotherapy with high-dose interleukin-2 (HD IL-...

see more →

Patient Education  2 results see all →